A Columbia University study evaluated whether HIV-infected children in South Africa who had achieved viral suppression with one antiretroviral treatment could transition to efavirenz-based therapy, the recommended drug for children older than three years, without risk of viral failure. The researchers reported that the treatment program resulted in excellent sustained virological control.
06 November 2015 | Eurekalert Inf Dis
Children infected with H.I.V. appear much more likely than those who are not to die with severe malaria, a new study has found. It may make sense to give these children malaria drugs protectively, the authors said.
01 October 2015 | New York Times
“Age doesn’t really impact your ability to swallow a pill,” said Dr. Kathleen Bradford, a professor of pediatrics at the University of North Carolina at Chapel Hill. “A teenager can have just as many problems as a 5-year-old. It likely has to do with anxiety and the negative associations with swallowing a pill.”
22 September 2015 | New York Times
HIV-positive children who have low CD4 counts when starting treatment by and large experience a rebound to normal levels of those immune cells. After two years on HIV meds, 92 percent of the children achieved a CD4 count of 500 or above. Just nine children (1 percent) experienced an AIDS-defining illness during treatment. Children starting with fewer than 200 CD4 cells/mm3 took 1.29 years to reach a CD4 count over 500 cells/mm3.
07 April 2015 | AIDSMeds
U.S. drugmaker Merck & Co has contributed an HIV medicine for children to an international shared patent pool in a move that should speed the development of cheap pediatric formulations for use in poor countries.
24 February 2015 | Reuters
HIV-positive children in developing countries are six times more likely to die from pneumonia than children without the virus, research suggests. The first global study into pneumonia deaths in children with HIV has found that, in one year, pneumonia affected 1.4 million children and led to a further 88,000 deaths.
07 January 2015 | Science Daily
The UNITAID Executive Board finished its twenty-first meeting and decided that UNITAID will invest up to $63 million through the Elizabeth Glaser Pediatric AIDS Foundation to bring early infant diagnosis for HIV to the heart of communities in nine African countries. This will pave the way to universal access for testing and enable a ten-fold increase in treatment, thus transforming global childhood HIV/AIDS. Initiating treatment before the twelfth week of life reduces HIV-related mortality by 75%.
17 December 2014 | UNITAID
Since the start of President Obama’s Administration, the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) has achieved a four-fold increase and is now providing 7.7 million people with life-saving antiretroviral (ARV) treatment worldwide. Despite this, only 1 in 4 of the 3.2 million children living with HIV/AIDS worldwide are today receiving treatment.
09 December 2014 | US Department of State
he licence will enable other companies and organisations to re-formulate and manufacture specially designed LPV/r and r paediatric treatments for distribution in low- and middle-income countries where 99% of children with HIV in the developing world live.
02 December 2014 | Medicines Patent Pool
Children starting antiretroviral therapy (ART) with a nonnucleoside (NNRTI) plus 3 nucleosides (NRTIs) had the lowest 2-year virologic failure rate in a study of 997 children in the United Kingdom and Ireland. Five-year toxicity rates were similar with the NNRTI and protease inhibitor (PI) regimens studied.
24 November 2014 | International AIDS Society